See more : Vitalibis, Inc. (VCBDQ) Income Statement Analysis – Financial Results
Complete financial analysis of Zynex, Inc. (ZYXI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zynex, Inc., a leading company in the Medical – Distribution industry within the Healthcare sector.
- Bobst Group SA (0QKJ.L) Income Statement Analysis – Financial Results
- Jiangxi Selon Industrial Co., Ltd. (002748.SZ) Income Statement Analysis – Financial Results
- Enel Generación Costanera S.A. (EDCFF) Income Statement Analysis – Financial Results
- Emmi AG (0QM5.L) Income Statement Analysis – Financial Results
- Grindwell Norton Limited (GRINDWELL.BO) Income Statement Analysis – Financial Results
Zynex, Inc. (ZYXI)
About Zynex, Inc.
Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and knee braces for knee support. Further, it offers Zynex Fluid Monitoring System (CM-1500), a fluid volume monitor, which is a non-invasive medical device for monitoring relative fluid volume changes used in operating and recovery rooms to detect fluid loss during surgery and internal bleeding during recovery; Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 184.32M | 158.17M | 130.30M | 80.12M | 45.47M | 31.92M | 23.43M | 13.31M | 11.64M | 11.12M | 21.68M | 39.67M | 34.15M | 24.09M | 18.68M | 11.76M | 8.05M | 2.56M | 2.26M | 1.26M | 0.00 | 0.00 | 0.00 | 160.88K | 0.00 | 12.41K | 89.49K |
Cost of Revenue | 38.37M | 32.01M | 27.32M | 17.42M | 8.81M | 6.04M | 4.82M | 3.52M | 4.94M | 7.61M | 8.14M | 8.77M | 7.37M | 5.20M | 3.79M | 2.24M | 729.05K | 303.72K | 309.63K | 237.64K | 0.00 | 0.00 | 0.00 | 232.37K | 0.00 | 6.21K | 44.59K |
Gross Profit | 145.96M | 126.16M | 102.98M | 62.71M | 36.66M | 25.88M | 18.61M | 9.80M | 6.70M | 3.51M | 13.54M | 30.90M | 26.78M | 18.88M | 14.89M | 9.52M | 7.32M | 2.25M | 1.95M | 1.02M | 0.00 | 0.00 | 0.00 | -71.49K | 0.00 | 6.21K | 44.90K |
Gross Profit Ratio | 79.19% | 79.77% | 79.03% | 78.26% | 80.62% | 81.08% | 79.43% | 73.58% | 57.59% | 31.53% | 62.46% | 77.89% | 78.41% | 78.40% | 79.69% | 80.96% | 90.94% | 88.12% | 86.29% | 81.09% | 0.00% | 0.00% | 0.00% | -44.43% | 0.00% | 50.00% | 50.18% |
Research & Development | 9.20M | 7.10M | 2.60M | 800.00K | 600.00K | 200.00K | 100.00K | 256.00K | 256.00K | 394.00K | 754.00K | 874.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 48.52M | 36.11M | 26.32M | 18.32M | 11.58M | 8.34M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 37.35K | 1.16M | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 86.66M | 67.12M | 54.29M | 34.13M | 14.02M | 6.39M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 13.34M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 351.16K | 0.00 | 0.00 | 0.00 |
SG&A | 125.98M | 103.22M | 80.61M | 52.46M | 25.59M | 15.51M | 9.67M | 9.16M | 9.19M | 11.40M | 21.14M | 28.16M | 23.68M | 17.32M | 11.07M | 9.21M | 4.00M | 2.33M | 1.88M | 1.91M | 35.52K | 22.72K | 37.35K | 1.51M | 25.28K | 17.18K | 47.40K |
Other Expenses | 0.00 | 0.00 | 0.00 | -77.00K | 880.00K | 0.00 | 0.00 | -204.00K | -7.00K | -47.00K | 77.00K | 31.00K | 0.00 | 0.00 | 0.00 | 0.00 | 153.44K | 94.01K | 64.80K | 80.03K | 0.00 | 0.00 | 0.00 | 13.26K | 122.00 | 366.00 | 71.27K |
Operating Expenses | 135.18M | 103.22M | 80.61M | 52.46M | 25.59M | 15.51M | 9.67M | 9.16M | 9.19M | 9.20M | 21.14M | 28.16M | 23.68M | 17.32M | 11.07M | 9.21M | 4.16M | 2.42M | 1.94M | 1.99M | 35.52K | 22.72K | 37.35K | 1.53M | 25.40K | 17.55K | 118.67K |
Cost & Expenses | 173.54M | 135.23M | 107.94M | 69.87M | 34.41M | 21.55M | 14.49M | 12.67M | 14.12M | 16.81M | 29.28M | 36.93M | 31.05M | 22.52M | 14.87M | 11.45M | 4.89M | 2.72M | 2.25M | 2.23M | 35.52K | 22.72K | 37.35K | 1.76M | 25.40K | 23.76K | 163.26K |
Interest Income | 0.00 | 440.00K | 95.00K | 19.00K | 5.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00K | 1.00K | 5.00K | 4.13K | 424.00 | 24.00 | 1.37K | 234.00 | 1.36K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 352.00 | 270.00 |
Interest Expense | 1.09M | 440.00K | 95.00K | 19.00K | 5.00K | 154.00K | 1.45M | 352.00K | 503.00K | 536.00K | 607.00K | 435.00K | 460.00K | 215.00K | 164.99K | 65.62K | 244.84K | 155.49K | 37.32K | 38.74K | 110.10K | 72.03K | 91.42K | 30.29K | 0.00 | 5.85K | 17.75K |
Depreciation & Amortization | 4.22M | 3.93M | 3.68M | 1.57M | 778.00K | 448.00K | 286.00K | 435.00K | 424.00K | 660.00K | 839.00K | 912.00K | 806.00K | 774.00K | 677.41K | 436.49K | 370.25K | 245.03K | 64.80K | 44.78K | 0.00 | 0.00 | 0.00 | 13.62K | 122.00 | 366.00 | 389.00 |
EBITDA | 15.00M | 26.18M | 22.37M | 11.75M | 11.84M | 10.82M | 9.23M | 871.00K | -2.06M | -5.08M | -6.68M | 3.68M | 3.77M | 2.32M | 4.67M | 761.02K | 3.32M | 77.32K | 403.18K | -924.04K | -35.52K | -22.72K | -37.35K | -1.58M | -25.28K | -10.62K | -73.11K |
EBITDA Ratio | 8.14% | 14.50% | 17.16% | 14.66% | 24.34% | 32.49% | 38.17% | 6.54% | -17.73% | -45.73% | -30.82% | 9.29% | 11.44% | 9.72% | 24.06% | 6.11% | 43.84% | 2.97% | -2.99% | -70.53% | 0.00% | 0.00% | 0.00% | -984.94% | 0.00% | -85.58% | -81.70% |
Operating Income | 10.78M | 22.94M | 22.37M | 10.25M | 11.07M | 10.37M | 8.94M | 640.00K | -2.48M | -5.70M | -7.60M | 2.74M | 3.10M | 1.56M | 3.81M | 309.18K | 3.16M | -167.71K | 6.41K | -968.83K | -35.52K | -22.72K | -37.35K | -1.60M | -25.40K | -11.34K | -73.77K |
Operating Income Ratio | 5.85% | 14.50% | 17.16% | 12.79% | 24.34% | 32.49% | 38.17% | 4.81% | -21.31% | -51.25% | -35.05% | 6.90% | 9.08% | 6.48% | 20.42% | 2.63% | 39.29% | -6.56% | 0.28% | -77.09% | 0.00% | 0.00% | 0.00% | -993.41% | 0.00% | -91.36% | -82.44% |
Total Other Income/Expenses | 1.80M | -740.00K | -95.00K | -96.00K | 875.00K | -154.00K | -1.45M | -556.00K | -510.00K | -583.00K | -530.00K | -401.00K | -457.00K | -226.00K | 9.49K | -38.22K | -240.98K | -152.66K | 101.55K | -39.89K | 35.52K | -72.03K | -91.42K | -30.29K | 0.00 | -5.50K | -17.48K |
Income Before Tax | 12.58M | 22.20M | 22.27M | 10.15M | 11.94M | 10.22M | 7.49M | 84.00K | -2.99M | -6.28M | -8.13M | 2.34M | 2.64M | 1.34M | 3.82M | 270.95K | 2.92M | -320.37K | 107.96K | -1.01M | -145.62K | -94.75K | -128.77K | -1.63M | -25.40K | -16.84K | -91.26K |
Income Before Tax Ratio | 6.82% | 14.03% | 17.09% | 12.67% | 26.26% | 32.01% | 31.98% | 0.63% | -25.69% | -56.49% | -37.49% | 5.89% | 7.74% | 5.54% | 20.47% | 2.30% | 36.30% | -12.53% | 4.78% | -80.27% | 0.00% | 0.00% | 0.00% | -1,012.24% | 0.00% | -135.65% | -101.98% |
Income Tax Expense | 2.85M | 5.15M | 5.17M | 1.08M | 2.45M | 664.00K | 129.00K | 15.00K | -57.00K | -49.00K | -790.00K | 788.00K | 1.08M | 985.00K | 1.44M | 160.00K | 790.00K | 152.66K | -101.55K | -32.84K | 145.62K | 94.75K | 0.00 | 0.00 | 0.00 | 352.00 | 270.00 |
Net Income | 9.73M | 17.05M | 17.10M | 9.07M | 9.49M | 9.55M | 7.37M | 69.00K | -2.91M | -6.20M | -7.30M | 1.55M | 1.56M | 350.00K | 2.38M | 110.95K | 2.13M | -320.37K | 107.96K | -975.88K | -145.62K | -94.75K | -128.77K | -1.63M | -25.40K | -16.84K | -91.26K |
Net Income Ratio | 5.28% | 10.78% | 13.13% | 11.33% | 20.87% | 29.93% | 31.43% | 0.52% | -25.01% | -55.76% | -33.67% | 3.92% | 4.58% | 1.45% | 12.75% | 0.94% | 26.48% | -12.53% | 4.78% | -77.66% | 0.00% | 0.00% | 0.00% | -1,012.24% | 0.00% | -135.65% | -101.98% |
EPS | 0.27 | 0.44 | 0.41 | 0.24 | 0.27 | 0.27 | 0.21 | 0.00 | -0.08 | -0.18 | -0.21 | 0.05 | 0.05 | 0.01 | 0.07 | 0.00 | 0.07 | -0.01 | 0.01 | -0.04 | -0.01 | -0.64 | -81.97 | -682.53 | -18.07 | 0.00 | -21.77 |
EPS Diluted | 0.27 | 0.44 | 0.40 | 0.24 | 0.25 | 0.26 | 0.20 | 0.00 | -0.08 | -0.18 | -0.21 | 0.05 | 0.05 | 0.01 | 0.07 | 0.00 | 0.06 | -0.01 | 0.01 | -0.04 | -0.01 | -0.64 | -81.97 | -682.53 | -18.07 | 0.00 | -21.77 |
Weighted Avg Shares Out | 35.56M | 38.47M | 42.15M | 37.26M | 35.68M | 35.75M | 35.37M | 34.40M | 34.40M | 34.10M | 34.27M | 34.17M | 33.83M | 33.60M | 33.13M | 31.89M | 29.26M | 26.43M | 25.43M | 25.00M | 24.37M | 148.53K | 1.57K | 2.39K | 1.41K | 35.75M | 4.19K |
Weighted Avg Shares Out (Dil) | 36.14M | 39.13M | 43.12M | 38.44M | 37.36M | 37.45M | 36.52M | 34.40M | 34.40M | 34.33M | 34.27M | 34.34M | 34.08M | 33.78M | 33.41M | 33.69M | 31.30M | 26.43M | 25.43M | 25.00M | 24.37M | 148.53K | 1.57K | 2.39K | 1.41K | 37.45M | 4.19K |
Zynex's strategic shifts set stage for long-term success, analysts say
Zynex CEO reflects on 28 years of medical device innovation - ICYMI
Zynex Stock Rises on FDA Clearance of Its New Pain Management Device
Zynex to Present at the HC Wainwright Global Investment Conference
Zynex pain management device TensWave achieves FDA clearance
Zynex Obtains FDA clearance for new Pain Management Device
Zynex's bold expansion in patient monitoring technologies moves from vision to reality
Why Zynex Plunged Today
Why Is Zynex (ZYXI) Stock Down 24% Today?
DexCom, Zynex, Olin And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Source: https://incomestatements.info
Category: Stock Reports